The work of the Center for Proteomic Chemistry (CPC) lies at the intersection of the chemical and biological universes: CPC's mission is the systematic study of the interactions of small chemical molecules with biological macromolecules, generally proteins. One major focus of CPC is 'lead finding' - the identification of chemical compounds as starting points for medicinal chemistry that can then be optimized further into candidates for clinical development.
CPC collaborates closely with all of NIBR's departments, applying the suitable combination of lead finding approaches to each drug discovery project. These include high- and medium-throughput screening, structural biology, fragment-based drug discovery, biophysics, and various in silico approaches.
In partnership with Global Discovery Chemistry (GDC), CPC is the steward of the Novartis Compound Bank, a collection of over one million chemical compounds. Also, CPC operates the IT and automation infrastructure for most compound logistics at NIBR.
Natural products - chemical compounds isolated from various natural sources such as microbes, fungi, and plants - are a special part of the compound collection. Their identification, isolation, and study are the focus of the CPC's Natural Products Unit (NPU).
Also part of CPC is the Expertise Platform Proteases (EPP), which was established to study an important target family, proteases. Many biological targets belong to distinct molecular families and tend to interact with small compounds in a very similar way, making it possible to apply lessons learned from one target to other similar targets and thus making drug discovery faster and more efficient.
CPC's scientific activities are made possible by substantial expertise in assay automation, compound logistics, information technology, cheminformatics, and the management and interpretation of vast amounts of experimental data.
Novel trends in high-throughput screening. Mayr L, Bojanic D. Curr. Op. Pharm. 2009, 9, 580-588.
Protease-directed drug discovery. Sedrani R, Hommel U, Eder J. Gene Family Targeted Molecular Design. Edited by Lackey KE. 2009: 159-97.
Natural products as catalysts for innovation: a pharmaceutical industry perspective. Schmitt E, Moore C, Krastel P, Petersen F. Curr Opin Chem Biol. 2011 Jun 18.
Understanding the underlying molecular basis of disease has enabled NIBR to turn scientific insights into medical breakthroughs.
Global Discovery Chemistry
Drug discovery and development process